LifeTech Scientific Corporation announced that on 16 August 2023, the Epione ® Surgical Navigation System, introduced by Dongguan LifeTech-Quantum Medical Technology Co. Ltd. obtained official registration approval by the China National Medical Products Administration ("NMPA"). The Product is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of rigid straight instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedure.

It can provide stable, accurate, and repeatable instrument navigation, which can simplify the operation and reduce the operative risk. Epione is designed to improve operation efficiency, reduce needle adjustments, reduce radiation dose, and reduce the probability of complications, which has great value especially for the treatment of complex lesions. In September 2021, Epione obtained the European CE certification, and it was approved by the US Food and Drug Administration (the "FDA") for the treatment of liver cancer in March 2022, and also received approval by the FDA for the extension of application scope to all abdominal tumors in May 2023.

In August 2023, Epione ® obtained registration approval by the NMPA, with indications covering all abdominal organs. Epione is an open robotic solution that is compatible with various treatment methods such as tumor ablation, biopsy, and particle implantation. For tumor ablation surgery, the design of Epione ® allows doctors to choose different ablative technologies so that they can determine the right therapy for each individual.

The goal of Epione ® is to dramatically ease multiple probe procedures, which will make the treatment of large tumors more predictable. Additionally, the arm of Epione ® offers 6 degrees of freedom and unprecedented dexterity to access difficult trajectories when targeting abdominal tumors. Epione ® has gradually been applied in clinical treatment in Europe and the United States.

It is expected that over 4 million patients worldwide will be able to benefit from Epione ® treatment. The Group will continue with independent innovation, and work with industry experts to advance the development and marketing of innovative medical device products to benefit a large number of patients.